Evaluation of an electronic diary for improvement of adherence to interferon beta-1b in patients with multiple sclerosis: Design and baseline results of an observational cohort study

BMC Neurology

Volumn 13, Issue , 2013, Pages

  Zettl, Uwe K ^a   Bauer Steinhusen, Ulrike ^b   Glaser, Thomas ^b   Hechenbichler, Klaus ^c   Limmroth, Volker ^d  

^a ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^b BAYER AG   (Germany)

^c Institut Dr Schauerte   (Germany)

^d Biochem Abtig II Chir Lehrstuhl   (Germany)

Author keywords

Adherence; Electronic diary; Immunomodulation; Interferon beta 1b; Multiple sclerosis; Non interventional study

Indexed keywords

INTERFERON BETA SERINE;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE DURATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PROSPECTIVE STUDY; RATING SCALE; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANXIETY; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; DEPRESSION; ELECTRONIC HEALTH RECORDS; FEMALE; HUMANS; INTERFERON-BETA; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MULTIPLE SCLEROSIS; OBSERVATION; SELF ADMINISTRATION; TIME FACTORS; TREATMENT OUTCOME;

EID: 84883517464     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-13-117     Document Type: Article

References (32)

1. Sabate E. Adherence to longterm therapies - Evidence for action 2003, Geneva: World Health Organization.
2. Vermeire E, Hearnshaw H, van Royen P, Denekens J. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther 2001, 26:331-42. 10.1046/j.1365-2710.2001.00363.x, 11679023.
3. Golay A. Pharmacoeconomic aspects of poor adherence: can better adherence reduce health care costs?. J Med Econ 2011, 14:594-608. 10.3111/13696998.2011.597808, 21732903.
4. Osterberg L, Blaschke T. Adherence to medication. New Engl J Med 2005, 353:487-97. 10.1056/NEJMra050100, 16079372.
5. Kern S, Reichmann H, Ziemssen T. Therapieadhärenz in der neurologischen Praxis. Nervenarzt 2008, 79:877-90. 10.1007/s00115-008-2419-0, 18335191.
6. Klauer T, Zettl UK. Compliance, adherence, and the treatment of multiple sclerosis. J Neurol 2008, 255(Suppl 6):87-92.
7. Ivanova JI, Bergman RE, Birnbaum HG, Phillips AL, Stewart M, Meletiche DM. Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US. J Med Econ 2012, 15:601-09. 10.3111/13696998.2012.667027, 22376190.
8. Tremlett H, van der Mei I, Fotini P, Blizzard L, Paley G, Dwyer T, Taylor B, Ponsonby AL. Adherence to the immunmodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses. Pharmaepidemiol Drug Saf 2008, 17:565-76.
9. Steinberg SC, Faris RJ, Chang CF, Chan A, Tankersey MA. Impact of adherence to interferons in the treatment of multiple sclerosis. Clin Drug Invest 2010, 30:89-100.
10. Treadaway K, Cutter G, Salter A, Lynch S, Simsarian J, Corboy J, Jeffery D, Cohen B, Mankowski K, Guarnaccia J, Schaeffer L, Kanter R, Brandes D, Kaufman C, Duncan D, Marder E, Allen A, Harney J, Cooper J, Woo D, Stüve O, Racke M, Frohmann EM. Factors that influence adherence with disease-modifying therapy in MS. J Neurol 2009, 256:568-576. 10.1007/s00415-009-0096-y, 19444532.
11. Bischoff C, Schreiber H, Bergmann A. Background information on multiple sclerosis patients stopping ongoing immunmodulatory therapy: a multicenter study in a community-based environment. J Neurol 2012, 259:2347-53. 10.1007/s00415-012-6499-1, 22527237.
12. Portaccio E, Amato PM. Improving compliance with interferon-β therapy in patients with multiple sclerosis. CNS Drugs 2009, 23:453-62. 10.2165/00023210-200923060-00001, 19480465.
13. Devonshire V, Lapierre Y, Macdonell R, Ramo-Tello C, Patti F, Fontoura P, Suchet L, Hyde R, Balla I, Frohmann EM, Kieseier BC. The Global adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol 2010, 18:69-77.
14. Fernández O, Agüera J, Izquierdo G, Millán-Pascual J, Ramio i Torrentà L, Oliva P, Argente J, Berdei Y, Soler JM, Carmona O, Errea JM, Farrés J. Adherence to interferon beta-1b treatment in patients with multiple sclerosis in Spain. PLOS One 2012, 7:e35600. 10.1371/journal.pone.0035600, 3353967, 22615737.
15. Mondorf W, Siegmund B, Mahnel R, Richter H, Westfeld M, Galler A, Pollmann H. Haemoassist - a hand-held electronic patient diary for haemophilia home care. Haemophilia 2009, 15:464-72. 10.1111/j.1365-2516.2008.01941.x, 19226411.
16. Goldberg J, Wolf A, Silberstein S, Gebeline-Myers C, Hopkins M, Einhorn K, Tolosa JE. Evaluation of an electronic diary as a diagnostic tool to study headache and premenstrual symptoms in migraineurs. Headache 2007, 47:384-96.
17. Giffin NJ, Ruggiero L, Lipton RB, Silberstein SD, Tvedskov JF, Olesen J, Altman J, Goadsby PJ, Macrae A. Premonitory symptoms in migraine: an electronic diary study. Neurology 2003, 25:935-40.
18. Cella DF, Dineen K, Arnason B, Reder A, Webster KA, Karabatsos G, Chang C, Lloyd S, Steward J, Stefoski D. Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology 1996, 47:129-39. 10.1212/WNL.47.1.129, 8710066.
19. Radloff LS. The CES-D Scale: a self-report depression for research in the general population. Appl Psychol Meas 1977, 1:385-401.
20. Weissmann MM, Sholomskas D, Pottenger M, Prusoff BA, Locke BZ. Assessing depressive symptoms in five psychiatric populations: a validation study. Am J Epidemiol 1977, 106:203-14.
21. Pandaya R, Metz L, Patten SB. Predictive value of the CES-D in detecting depression among candidates for disease-modifying multiple sclerosis treatment. Psychosomatics 2005, 46:131-34. 10.1176/appi.psy.46.2.131, 15774951.
22. Flachenecker P, Müller G, König H, Meissner H, Toyka K, Rieckmann P. " Fatigue" bei Multipler Sklerose. Entwicklung und Validierung des " Würzburger Erschöpfungsinventars bei MS" Nervenarzt 2006, 77:165-174. 10.1007/s00115-005-1990-x, 16160812.
23. Kind P. The EuroQuol instrument: an index of health-related quality of life. Quality of Life and Pharmacoeconomics in Clinical Trials 1996, 191-201. Philadelphia: Lippincott-Raven Publ, Spilker B, Second Edition.
24. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33:1444-52. 10.1212/WNL.33.11.1444, 6685237.
25. Bussfeld P, Czekalla J. Therapieadhärenz bei Multipler Sklerose und Schizophrenie. Fortschr Neurol Psychiat 2010, 78:139-46. 10.1055/s-0029-1245148, 20213580.
26. Dickhaeuser O, Stiensmeier-Pelster J, Kemke K, Juergens N. Geschlechtsunterschiede in der Computernutzung. Paedagogische Psychologie unter gewandelten gesellschaftlichen Bedingungen 2002, 101-112. Universität Giessen: Schriften zur paedagogischen Psychologie, Spinath B, Heise E.
27. Wynia MK, Williams Torres G, Lemieux J. Many physicians are willing to use patient's electronic personal health records, but doctors differ by location, gender, and practice. Health Affairs 2011, 30:266-273. 10.1377/hlthaff.2010.0342, 21289348.
28. Patten SB, Lavorato DH, Metz LM. Clinical correlates of CES-D depressive symptom ratings in a MS population. Gen Hosp Psychiatry 2005, 27:439-45. 10.1016/j.genhosppsych.2005.06.010, 16271659.
29. Patten SB, Metz LM, Reimer MA. Biopsychosocial correlates of major depression in a multiple sclerosis population. Mult Scler 2000, 6:115-20.
30. Chwastiak L, Ehde DM, Gibbons LE, Sullivan M, Bowen JD, Kraft GH. Depressive symptoms and severity of illness in multiple sclerosis: Epidemiologic study of a large community sample. Am J Psychiatry 2002, 159:1862-68. 10.1176/appi.ajp.159.11.1862, 12411220.
31. Kessler RC, McGonagle KA, Swartz M, Blazer DG, Nelson CB. Sex and depression in the national Comorbidity Survey, I: lifetime prevalence, chronicity and recurrence. J Affect Disord 1993, 29:85-96. 10.1016/0165-0327(93)90026-G, 8300981.
32. Mohr DC, Goodkin DE, Likosky W, Gatto N, Baumann KA, Rudick RA. Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurol 1997, 54:53. 10.1001/archneur.1997.00550130037013, 9006414.